Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|October 6, 2022
Ashland Announces Klucel xtend HPC Matrix Former
Author(s)Pharmaceutical Technology Editors
Klucel xtend HPC is the latest addition to the company’s Klucel product line and further expands their controlled-release portfolio.
Advertisement
Ashland announced the introduction of Klucel xtend hydroxypropyl cellulose (HPC) controlled release matrix former on Oct. 3, 2022. It is designed to deliver process versatility and release profile efficiency.
According to a company press release, Klucel xtend HPC has been shown to match the release profile of widely used Hypromellose controlled-release formulations at half the polymer concentration. Prior to this product launch, Ashland claims that there were limited options for managing the release profile of controlled release formulations, especially high dose.
The reduced polymer concentration offers the possibility of smaller pills or higher dosage, presenting an option for easier tablet swallowability or a reduction in the number of tablets required for frequent medication. According to the release, this feature is intended to improve patient compliance with drug regimens.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement